Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma
Open Access
- 26 January 2022
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 12 (2) , 165
Abstract
Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning its efficacy and safety and its association with other asthma-related and drug-related parameters. Evidence suggests that omalizumab improves asthma control and reduces the incidence and frequency of exacerbations in patients with severe allergic asthma. Omalizumab is also effective in those patients in reducing corticosteroid use and healthcare utilization, while it also seems to improve lung function. Several biomarkers have been recognized in predicting its efficacy in its target group of patients, while the optimal duration for evaluating its efficacy is between 16 and 32 weeks.Keywords
This publication has 220 references indexed in Scilit:
- The eXpeRience registry: The ‘real-world’ effectiveness of omalizumab in allergic asthmaRespiratory Medicine, 2013
- Effectiveness of Omalizumab in Severe Allergic Asthma: A Retrospective UK Real-World StudyJournal of Asthma, 2013
- Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter RegistryJournal of Asthma, 2013
- A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Omalizumab on Asthma Control in Patients with Persistent Allergic AsthmaJournal of Asthma, 2012
- Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgEBritish Journal of Clinical Pharmacology, 2011
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Safety of anti‐immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infectionClinical & Experimental Allergy, 2007
- Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- OmalizumabDrugs, 2001